Introducing Medisca Nutraceuticals

Download in electronic PDF format for $25



Search the Complete Journal Archives

Stability of Memantine in an Extemporaneously Prepared Oral Liquid

Author(s):  Yamreudeewong Weeranuj, Teixeira M Glaucia, Mayer Gabriele E

Issue:  Jul/Aug 2006 - Sterile Preparations
View All Articles in Issue

Abstract:  Memantine, a N-methyl-D-aspartate receptor antagonist, was recently approved by the United States Food and Drug Administration for the palliative treatment of moderate to severe Alzheimer’s disease. Its suggested mechanism of action in the treatment of Alzheimer’s disease is binding to N-methyl-D-aspartate receptors, which results in inhibition of glutamate activity. Glutamate has been reported to contribute to the pathogenesis of Alzheimer’s disease by overstimulating the N-methyl-D-aspartate receptors, resulting in brain cell damage. The stability of memantine in an extemporaneously prepared oral liquid was studied. An aqueous liquid formulation was prepared by reconstituting memantine powder from triturated tablets with deionized water. The expected memantine concentration was 0.166 mg/mL. The memantine liquid was transferred into two glass prescription bottles; one was stored at room temperature (25°C), and the other in the refrigerator (2°C). Aliquots from each bottle were analyzed in quadruplicate on days 0, 1, 2, 3, 4, 7, 14, and 28 by using a gas chromatograph-mass spectrometer. The results of this study indicate that the extemporaneously prepared memantine oral liquid was stable for up to 7 days at room temperature and up to 28 days in the refrigerator.

Related Keywords: Weeranuj Yamreudeewong, PharmD, M. Glaucia Teixeira, PhD, Gabriele E. Mayer, PhD, memantine, N methyl D aspartate receptor antagonist, NMDA blocker, Alzheimer's disease, dementia, liquid formulation, stability

Related Categories: PEER-REVIEWED, STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS, NEUROLOGY, STORAGE

Printer-Friendly Version

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Stability of Memantine in an Extemporaneously Prepared Oral Liquid Yamreudeewong Weeranuj, Teixeira M Glaucia, Mayer Gabriele E Jul/Aug 2006 316-317 Buy
Stability of Clopidogrel in Three Extemporaneously Compounded Oral Liquid Preparations Yamreudeewong Weeranuj, Dolence Eric Kurt, Teizeira M Glaucia Sep/Oct 2011 435-437 Buy
Book Review: The NMDA Receptor Jones Marty Jan/Feb 2000 26-27 Buy
Compounded Pain Formulations: What is the Evidence? Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso Jul/Aug 2014 278-286 Buy
Basics of Compounding for Raynaud's Disease Glasnapp Andrew Jul/Aug 2003 288 Buy
The Treatment of Canine Atopic Disease Davidson Gigi S May/Jun 2002 210-215 Buy
Dextromethorphan, an NMDA receptor antagonist, as a Treatment for Pain Mishkan Emilyn S Sep/Oct 2005 339-346 Buy
Estrogen Replacement Therapy in the Treatment of Alzheimer's Disease Osburn Jennifer May/Jun 2002 171-176 Buy
Treating Canine Hepatic Disease Davidson Gigi S May/Jun 2003 188 Buy
Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review Beshay Sarah M, Rivera Gerard, Balthasar Jan, Florea Naomi Jul/Aug 2015 295-300 Buy